Through joint collaborations with top pharmaceutical companies and research institutions, KREX has been used to identify autoantibody biomarkers for commercial precision immuno-profiling and screening applications. In addition, KREX has also been used to identify biologics with therapeutic potential.
High-throughput autoantibody profiling against 1600+ proteins
Quantification of autoantibodies to 200+ clinically relevant CT antigens
Simultaneous screening of 100+
wild-type and mutant p53
COVID-19 antibody test